natgillin/translations-raw huggingface dataset:
Driving and using machines DuoPlavin should not affect your ability to drive or to use machines.
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo DuoPlavin ne bi smelo vplivati na vašo sposobnost za vožnjo ali upravljanje strojev.
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
• preobčutljivosti za zdravilni učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1,
Other medicines and DuoPlavin
Druga zdravila in zdravilo DuoPlavin
What you need to know before you take DuoPlavin
Kaj morate vedeti, preden boste vzeli zdravilo DuoPlavin
DuoPlavin has no or negligible influence on the ability to drive and use machines.
Zdravilo DuoPlavin nima ali ima zanemarljiv vpliv na sposobnost za vožnjo in upravljanje strojev.
This randomized, open-label trial included ACS patients requiring PCI.
To randomizirano, odprto preskušanje je vključilo bolnike z AKS, ki so potrebovali PKI.
The population included 27.8% women, 58.4% patients ≥60 years (26% ≥70 years) and 54.5% patients who received fibrinolytics.
Populacijo bolnikov je sestavljalo 27,8 % žensk, 58,4 % bolnikov starost ≥ 60 let (26 % ≥ 70 let ) in 54,5 % bolnikov, ki so dobivali fibrinolitike.
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel plus ASA group and 363 (5.8%) in the ASA group].
Ta korist je bila v glavnem zaradi statistično pomembnega zmanjšanja incidence MI [287 (4,6 %) v skupini, zdravljeni s klopidogrelom in ASA, in 363 (5,8 %) v skupini z ASA].
Apart from the specific medicinal product interaction information described above, interaction studies with DuoPlavin and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed.
Razen navedenih informacij o specifičnih interakcijah z zdravili, študij o interakcijah zdravila DuoPlavin in nekaterih zdravil, ki jih pogosto uporabljajo bolniki z aterotrombotično boleznijo ni bilo.
It also contains: lactose and hydrogenated castor oil.
Vsebuje tudi laktozo in hidrogenirano ricinusovo olje.
Salicylic acid in DuoPlavin has a plasma half-life of approximately 2 hours.
Salicilna kislina iz zdravila DuoPlavin ima plazemski razpolovni čas približno 2 uri.
Until the 24th amenorrhea week (5th month of pregnancy), acetylsalicylic acid should not be given unless clearly necessary.
Do 24. tedna amenoreje (5. meseca nosečnost) se acetilsalicilne kisline ne sme uporabljati, če ni nujno potrebno.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking DuoPlavin.
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti zdravnika ali farmacevta, preden vzamete zdravilo DuoPlavin.
A patient with poor metaboliser status will possess two loss-offunction alleles as defined above.
Bolnik, ki je slab metabolizator, ima dva hipofunkcijska alela, kot je pojasnjeno zgoraj.
Breast-feeding should be discontinued during treatment with DuoPlavin.
Dojenje je med zdravljenjem z zdravilom DuoPlavin potrebno prekiniti.
DuoPlavin prolongs bleeding time and should be used with caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal and intraocular).
Zdravilo DuoPlavin podaljša čas krvavitve in ga je potrebno previdno uporabljati pri bolnikih z lezijami, ki so nagnjene h krvavitvi (zlasti gastrointestinalne in intraokularne).
No clinical data on exposure to DuoPlavin during pregnancy are available.
Kliničnih podatkov o izpostavljenosti zdravilu DuoPlavin v nosečnosti ni na voljo.
• the mother and the neonate, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labour.
• mater in novorojenčka na koncu nosečnosti: - možnemu podaljšanju časa krvavitve, antiagregacijskemu učinku, ki se lahko pojavi celo po zelo majhnih odmerkih, - zavrtju krčenja maternice in zaradi tega odloženemu ali podaljšanemu porodu.
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure.
Ker kliničnih podatkov o izpostavljenosti klopidogrelu med nosečnostjo ni, je kot previdnostni ukrep zaželeno, da se klopidogrela med nosečnostjo ne uporabljate.
Therefore, this combination should be used with caution in patients taking low dose ASA for cardioprotection .
Zato je to kombinacijo treba uporabljati previdno pri bolnikih, ki jemljejo nizke odmerke acetilsalicilne kisline za zaščito srca.
Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy.
Podatki epidemioloških študij kažejo večje tveganje spontanih splavov, malformacij srca in gastroshize po uporabo zaviralcev sinteze prostaglandinov v zgodnji nosečnosti.
Adverse reactions that occurred with clopidogrel alone, with ASA alone or with clopidogrel in combination with ASA either during clinical studies or that were spontaneously reported are presented in the table below.
Neželeni učinki, zabeleženi samo s klopidogrelom, samo z ASA ali s klopidogrelom v kombinaciji z ASA v kliničnih študijah ali opisani spontano, so našteti v spodnji tabeli.
- if you have any stomach or abdominal pain or bleeding in the stomach or bowels (red stools or black stools).
- če imate bolečine v želodcu ali trebuhu ali krvavitev v želodec ali črevo (rdeče blato ali črno blato).
• Severe renal impairment (creatinine clearance <30 ml/min).
• pri bolnikih s hudo okvaro ledvic (očistek kreatinina <30 ml/min),
1, rue de la Vierge, Ambarès & Lagrave, F-33565 Carbon Blanc cedex, France
1, Rue de la Vierge, Ambarès & Lagrave, F-33565 Carbon Blanc cedex, Francija
For the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow.
Morda vam je zdravnik za zdravljenje vaše bolezni v zamašeno ali zoženo arterijo namestil žilno opornico ("stent"), da bi obnovil ustrezen pretok krvi.
DuoPlavin is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA).
Zdravilo DuoPlavin je indicirano za sekundarno preprečevanje aterotrombotičnih dogodkov pri odraslih bolnikih, ki že jemljejo klopidogrel in acetilsalicilno kislino (ASA).
Store below 25C.
Shranjujte pri temperaturi do 25C.
Minor GI symptoms, such as dyspepsia, are common and can occur anytime during therapy.
Manj izraziti gastrointestinalni simptomi npr. dispepsija, so sicer pogosti in se lahko pojavijo kadarkoli med zdravljenjem.
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure.
Zelo redko so po uporabi klopidogrela poročali o trombotični trombocitopenični purpuri (TTP), ki se je včasih pojavila že po kratki izpostavljenosti.
DuoPlavin is taken by adults to prevent blood clots forming in hardened arteries which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Zdravilo DuoPlavin jemljejo odrasli za preprečevanje nastanka krvnih strdkov v otrdelih krvnih žilah, ki lahko vodi do aterotrombotičnih dogodkov (kot so kap, srčni napad ali smrt).
Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel plus ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4).
Tako se pri zdravljenju več kot 3 mesece opažena korist v skupini, ki je prejemala klopidogrel in ASA, ni nadalje povečevala, medtem ko je tveganje za krvavitev ostala (glejte poglavje 4.4).
• if you are allergic to other products called non-steroidal anti-inflammatory products usually used to treat painful and/or inflammatory conditions of muscles or joints.
• če ste alergični na druga zdravila, t. i. nesteroidna protivnetna zdravila, ki jih ponavadi uporabljamo za zdravljenje bolečih in/ali vnetja mišic ali sklepov,
• if you are allergic to clopidogrel, acetylsalicylic acid (ASA) or any of the other ingredients of this medicine (listed in section 6).
• če ste alergični na klopidogrel, acetilsalicilno kislino (ASA) ali katero koli sestavino tega zdravila
Do not take DuoPlavin during third trimester of pregnancy.
Zdravila DuoPlavin ne smete jemati v tretjem trimesečju nosečnosti.
The safety and efficacy of clopidogrel plus ASA have been evaluated in three double-blind studies involving over 61,900 patients: the CURE, CLARITY and COMMIT studies, comparing clopidogrel plus ASA to ASA alone, both treatments given in combination with other standard therapy.
Varnost in učinkovitost klopidogrela in ASA so vrednotili v treh dvojno slepih raziskavah, v katere je bilo vključenih več kot 61.900 bolnikov: CURE, CLARITY in COMMIT, ki so primerjale kombinacijo klopidogrela in ASA s samo ASA; oboje so bolniki dobivali v kombinaciji z drugo standardno terapijo.
Due to the presence of ASA, methotrexate used at doses higher than 20 mg/week should be used with caution with DuoPlavin as it can inhibit renal clearance of methotrexate, which may lead to bone marrow toxicity.
Zaradi vsebnosti ASA je med sočasno uporabo metotreksata, ki se uporablja v odmerku višjem od 20 mg/teden, z zdravilom DuoPlavin potrebna previdnost, ker lahko zavre ledvični očistek metotreksata in tako povzroči toksične učinke na kostni mozeg.
Clopidogrel plus ASA significantly reduced the relative risk of death from any cause by 7% (p = 0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p = 0.002), representing an absolute reduction of 0.5% and 0.9%, respectively.
Klopidogrel in ASA sta pomembno zmanjšala relativno tveganje za smrt zaradi kateregakoli vzroka za 7 % (p=0,029) in relativno tveganje za ponovni infarkt, kap ali smrt za 9 % (p=0,002), kar je predstavljalo absolutno zmanjšanje za 0,5 % oziroma 0,9 %.
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography.
Primarni opazovani dogodki so bili navzočnost zamašene arterija (povezane z infarktom) na angiogramu pred odpustom ali smrt ali ponovni miokardni infarkt pred koronarno angiografijo.
You have been prescribed DuoPlavin in place of the two separate medicines, clopidogrel and ASA, to help prevent blood clots because you have experienced a severe type of chest pain known as ‘unstable angina' or heart attack (myocardial infarction).
Zdravnik vam je predpisal zdravilo DuoPlavin namesto dveh posameznih zdravil klopidogrela in ASA, kot pomoč za preprečevanje nastanka krvnih strdkov, ker ste imeli hudo obliko bolečine v prsih, znano kot "nestabilna angina pektoris", ali ker ste imeli srčni infarkt (miokardni infarkt).
If you become pregnant while taking DuoPlavin, consult your doctor immediately as it is recommended not to take DuoPlavin while you are pregnant.
Če med zdravljenjem z zdravilom DuoPlavin zanosite, se takoj posvetujte z zdravnikom, kajti jemanje zdravila DuoPlavin med nosečnostjo ni priporočljivo.
Due to the presence of ASA, DuoPlavin is contraindicated during the third trimester of pregnancy.
Zaradi vsebnosti ASA je zdravilo DuoPlavin kontraindicirano v tretjem trimesečju nosečnosti.
• the foetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;
• plod: - kardiopulmonalnim toksičnim učinkom (s prezgodnjim zaprtjem arterioznega duktusa in pljučno hipertenzijo), - motenemu delovanju ledvic, ki lahko napreduje v odpoved ledvic in oligohidramnij,
If you take more DuoPlavin than you should
Če ste vzeli večji odmerek zdravila DuoPlavin, kot bi smeli:
The use of clopidogrel in CURE was associated with a decrease in the need for thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%).
Uporaba klopidogrela v CURE je bila povezana z zmanjšano potrebo po zdravljenju s trombolitiki (zmanjšanje RT= 43,3 %; IZ: 24,3 %, 57,5 %) in inhibitorji glikoproteinov IIb/IIIa (zmanjšanje RT =18,2 %; IZ: 6,5 %, 28,3 %).
What DuoPlavin is and what it is used for What you need to know before you take DuoPlavin How to take DuoPlavin
Kaj je zdravilo DuoPlavin in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo DuoPlavin Kako jemati zdravilo DuoPlavin Možni neželeni učinki
The recommended dose is one tablet of DuoPlavin per day to be taken orally with a glass of water, with or without food.
Priporočeni odmerek je ena tableta zdravila DuoPlavin na dan. Tableto vzemite s kozarcem vode.
Uncommon side effects (may affect up to 1 in 100 people):
Občasni neželeni učinki (pojavijo se lahko pri največ 1od 100 bolnikov):
For the 14, 28 and 84 tablets pack sizes you can check the day on which you last took a tablet of DuoPlavin by referring to the calendar printed on the blister.
Na koledarčku, ki je natisnjen na pretisnem omotu pakiranj po 14, 28 in 84 tablet, lahko preverite dan, ko ste nazadnje vzeli tableto zdravila DuoPlavin.
A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic (PK) interactions.
Druga zdravila: Številne druge klinične študije so izvedli s klopidogrelom in drugimi sočasno danimi zdravili, da bi proučili potencial za farmakodinamične in farmakokinetične interakcije.
After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 μM ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39% (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers.
Po odmerni shemi 300 mg/75 mg se je antiagregacijski odziv pri slabih metabolizatorjih zmanjšal: povprečno IPA (5 µM ADP) je bilo 24 % (24 ur) in 37 % (5. dan) v primerjavi z 39 % (24 ur) in 58 % (5. dan) pri dobrih metabolizatorjih ter 37 % (24 ur) in 60 % (5. dan) pri srednjih metabolizatorjih.
Kounis syndrome (vasospastic allergic angina / allergic myocardial infarction) in the context of a hypersensitivity reaction due to acetylsalicylic acid* or clopidogrel**
Kounisov sindrom (vazospastična alergijska angina / alergijski miokardni infarkt) v okviru preobčutljivostne reakcije zaradi acetilsalicilne kisline* ali klopidogrela**
Intracranial bleeding (some cases were reported with fatal outcome, especially in elderly), headache, paraesthesia, dizziness
Intrakranialna krvavitev (opisani so primeri s smrtnim izidom, zlasti pri starejših), glavobol, parestezije, omotica
Sanofi Winthrop Industrie 1 rue de la Vierge Ambarès et Lagrave F-33565 Carbon Blanc Cedex France
Sanofi Winthrop Industrie 1, Rue de la Vierge Ambarès et Lagrave F-33565 Carbon Blanc cedex Francija
(See section 4.5.)
(navedeno v poglavju 6),
Therefore DuoPlavin should be used with caution in these patients.
Zato je pri uporabi zdravila DuoPlavin pri the bolnikih potrebna previdnost.
In patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): The optimal duration of treatment has not been formally established.
Pri bolnikih z akutnim koronarnim sindromom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca): optimalno trajanje zdravljenja ni bilo formalno ugotovljeno.
TOPIC (Timing Of Platelet Inhibition after acute Coronary syndrome)
Študija TOPIC (Tempiranje zavrtja trombocitov po akutnem koronarnem sindromu)
Serious haemorrhage, haemorrhage of operative wound, vasculitis (including Henoch-Schönlein purpura*), hypotension
Resne krvavitve, krvavitev operacijske rane, vaskulitis (vključno s HenochSchönleinovo purpuro *), hipotenzija
5 How to store DuoPlavin Contents of the pack and other information
Shranjevanje zdravila DuoPlavin Vsebina pakiranja in dodatne informacije
It is unknown whether ASA dose in DuoPlavin alters fertility.
Ni znano, ali ASA v zdravilu DuoPlavin vpliva na plodnost.
Acute liver failure, liver injury, mainly hepatocellular*, hepatitis, elevation of hepatic enzymes*, abnormal liver function test, chronic hepatitis*
Akutna odpoved jeter, poškodba jeter, predvsem hepatocelularna*, hepatitis, zvišane vrednosti jetrnih encimov*, nenormalni testi jetrne funkcije, kronični hepatitis*
DuoPlavin should be used with caution in patients with a history of peptic ulcer or gastroduodenal haemorrhage or minor upper GI symptoms as this may be due to gastric ulceration which may lead to gastric bleeding.
Zdravilo DuoPlavin morate previdno uporabljati pri bolnikih z anamnezo peptične razjede, gastroduodenalne krvavitve ali manj izrazitih gastrointestinalnih simptomov zgornjega trakta, saj so ti simptomi lahko posledica želodčne razjede, ki lahko povzroči krvavitev v želodcu.
DuoPlavin contains clopidogrel and acetylsalicylic acid (ASA) and belongs to a group of medicines called antiplatelet medicinal products.
Zdravilo DuoPlavin vsebuje klopidogrel in acetilsalicilno kislino (ASA) in spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
Anaphylactic shock*, serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)**,insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)**, aggravation of allergic symptoms of food allergy*
Bolezni imunskega sistema anafilaktični šok*, serumska bolezen, anafilaktoidne reakcije, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4) **, avtoimuni inzulinski sindrom, ki lahko vodi v resno hipoglikemijo, še posebej pri bolnikih s HLA DRA4 podtipom (pogostejši v japonski populaciji)**, poslabšanje alergijskih simptomov alergije na hrano*
The guided de-escalation did not result in an increased combined risk of ischemic events (2.5% in the deescalation group vs 3.2% in the control group; p non-inferiority=0.0115), nor in the key secondary endpoint of BARC bleeding ≥2 ((5%) in the de-escalation group versus 6% in the control group
Vodena deeskalacija ni povečala ne kombiniranega tveganja za ishemične dogodke (2,5 % v skupini z deeskalacijo in 3,2 % v kontrolni skupini, p za neinferiornost = 0,0115) ne ključnega sekundarnega opazovanega dogodka, krvavitve ≥ 2 po BARC (5 % v skupini z deeskalacijo in 6 % v kontrolni skupini, p = 0,23).
Do not use this medicine after the expiry date which is stated on the carton and on the blister, after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila (glejte poglavje 6.1).
This medicinal product also contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Zdravilo vsebuje tudi hidrogenirano ricinusovo olje, ki lahko draži želodec in povzroči drisko.
Ask your doctor or pharmacist for advice before taking any medicine.
Posvetujete se z zdravnikom ali s farmacevtom, preden vzamete katero koli zdravilo.
DuoPlavin contains hydrogenated castor oil This may cause stomach upset or diarrhoea.
Zdravilo DuoPlavin vsebuje hidrogenirano ricinusovo olje To lahko povzroči želodčne motnje ali drisko.
DuoPlavin fixed-dose combination is used following initiation of therapy with clopidogrel and ASA given separately, and replaces the individual clopidogrel and ASA products.
DuoPlavin kombinirano zdravilo se uporablja po začetni ločeni terapiji s klopidogrelom in ASA, namesto posameznega klopidogrela ali ASA:
What DuoPlavin looks like and contents of the pack
Izgled zdravila DuoPlavin in vsebina pakiranja
Ulcer perforation, ringing in the ears, hearing loss, sudden life-threatening allergic or hypersensitivity reactions with chest or abdominal pain, kidney disease, low blood sugar, gout (a condition of painful, swollen joints caused by uric acid crystals) and worsening of food allergies, a particular form of anaemia (low number of red blood cells) (see section 2 ‘Warnings and precautions'), swelling.
Predrtje razjede, zvonjenje v ušesih, poslabšanje sluha, nenadne smrtno nevarne alergijske ali preobčutljivostne reakcije z bolečinami v prsih ali trebuhu, bolezen ledvic, nizek krvni sladkor, protin (stanje z bolečimi, oteklimi sklepi, ki ga povzročijo kristali sečne kisline) in poslabšanje alergij na hrano, posebna oblika anemije (nizko število rdečih krvnih celic) (glejte poglavje 2 ‘Opozorila in previdnostni ukrepi').
There are no fertility data with DuoPlavin.
Podatkov o plodnosti za zdravilo DuoPlavin ni.
• Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) and syndrome of asthma, rhinitis, and nasal polyps.
• pri bolnikih, preobčutljivih za nesteroidna protivnetna zdravila (NSAID) in bolnikih s sindromom astme, rinitisa in nosnih polipov.
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel plus ASA group and 719 (11.4%) in the ASA group, a 20% relative risk reduction (RRR) (95% CI of 10%-28%; p=0.00009) for the clopidogrel plus ASA group [17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)].
Delež bolnikov s primarnim opazovanim dogodkom [srčnožilna (SŽ) smrt, miokardni infarkt (MI) ali kap] je bil 582 (9,3 %) v skupini, zdravljeni s klopidogrelom in ASA, in 719 (11,4 %) v skupini, ki je prejemala ASA, to je 20 % zmanjšanje relativnega tveganja (95 % IZ od 10 % - 28 %; p=0,00009) v skupini, zdravljeni s klopidogrelom in ASA (17 % zmanjšanje relativnega tveganja, če so bili bolniki zdravljeni konzervativno, 29 % kadar je bila izvedena perkutana transluminalna koronarna angioplastika z ali brez stenta in 10 %, če je bila izvedena premostitvena operacija koronarnih arterijCABG).
If any of the situations mentioned below apply to you, you should tell your doctor before taking DuoPlavin:
Opozorila in previdnostni ukrepi Če karkoli od spodaj naštetega velja za vas, morate o tem povedati svojemu zdravniku, preden vzamete zdravilo DuoPlavin:
As a dual antiplatelet agent, DuoPlavin should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with other NSAIDs including Cox-2 inhibitors, heparin, glycoprotein IIb/IIIa inhibitors, selective serotonin reuptake inhibitors (SSRIs), thrombolytics, or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5).
Zdravilo DuoPlavin kot dvojno antiagregacijsko sredstvo je potrebno previdno uporabljati pri bolnikih s povečanim tveganjem krvavitev zaradi poškodbe, kirurškega posega ali drugih patoloških stanj in pri bolnikih, ki so na zdravljenju z drugimi nesteroidnimi protivnetnimi zdravili vključno z zaviralci COX2, heparinom, zaviralci glikoproteina IIb/IIIa, s selektivnimi zaviralci privzema serotonina (SSRI), trombolitiki ali z drugimi zdravili, ki so povezana s tveganjem za krvavitve, kot je pentoksifilin (glejte poglavje 4.5).
If you forget to take a dose of DuoPlavin, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.
Če pozabite vzeti odmerek zdravila DuoPlavin in se nanj spomnite v 12 urah od tedaj, ko bi ga morali vzeti, vzemite tableto takoj.